Brief: Synlogic Reports Fourth Quarter 2022 Results

Synlogic

29/03/2023 11:39

March 29 (Reuters) - Synlogic Inc  SYBX.O :
    * $77.6 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE
SECURITIES SUPPORT PROJECTED RUNWAY INTO SECOND HALF OF 2024
    * PHENYLKETONURIA (PKU) PROGRAM ON TRACK FOR PHASE 3 TRIAL
INITIATION IN FIRST HALF OF 2023
    * QTRLY LOSS PER SHARE $0.24
    * RARE PEDIATRIC DISEASE DESIGNATION GRANTED FOR SYNB1934
FOR PKU
AND SYNB1353 FOR HOMOCYSTINURIA (HCU)
    * Q4 EARNINGS PER SHARE VIEW $-0.26 -- REFINITIV IBES DATA


Further company coverage:  SYBX.O 

 ((Reuters.Briefs@thomsonreuters.com;))